Mirati Therapeutics is a clinical-stage oncology company developing therapeutics to address the genetic and immunological promoters of cancer. Co.'s product candidates include: Adagrasib, an investigational, selective, specific, potent and orally available KRAS G12C inhibitor in clinical development as a monotherapy and in combination with other agents; MRTX1133, an investigational, selective, specific and potent KRAS G12D inhibitor in preclinical development; Sitravatinib, an investigational spectrum-selective kinase inhibitor; and MRTX1719, an internally discovered investigational synthetic lethal PRMT5 inhibitor to target the PRMT5/methylthioadensoine complex in preclinical development. We show 43 historical shares outstanding datapoints in our MRTX shares outstanding history coverage, used to compute MRTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MRTX market cap history over the course of time is important for investors
interested in comparing MRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MRTX versus a peer is one thing; comparing
MRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MRTX can fluctuate over the course of history.
With this page we aim to empower investors researching MRTX by allowing them to research the MRTX market cap history. |
Free MRTX Email Alerts:
Video: The Importance of Market Cap
